Trends in Pharmacological Sciences
News & CommentThe nigrostriatal dopamine system: a neglected target for 5-HT2C receptors
Section snippets
Chemical names
MK212 6-chloro-2-(1-piperazinyl)piperazine Ro600175 (S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methyl-ethylamine SB206553 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole SB242084 6-chloro-5-methyl-1-[2-(2-methylpyridiyl-3-oxy)-pyrid-5-yl carbamoyl]-indoline
References (15)
Role of 5-HT2C receptors in the control of central dopamine function
Trends Pharmacol. Sci.
(2001)Selective blockade of serotonin2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study
Neuroscience
(1999)SB242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
Neuropharmacology
(1999)The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used
Neuropharmacology
(2000)Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra pars reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
Exp. Neurol.
(1998)- et al.
Effects of the 5-HT2C/2B antagonist SB206553 on hyperactivity induced by cocaine
Neuropsychopharmacology
(1999) - et al.
Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens
Brain Res.
(1998)
Cited by (37)
Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence
2021, Progress in Brain ResearchConstitutive activity of 5-HT receptors: Factual analysis
2020, NeuropharmacologyWhere in the serotonergic system does it go wrong? Unravelling the route by which the serotonergic system affects feather pecking in chickens
2018, Neuroscience and Biobehavioral ReviewsCitation Excerpt :It is known that 5-HT receptors can influence DA release from mesolimbic dopaminergic neurons in mammals (Fink and Göthert, 2007). The postsynaptic 5-HT1A receptor is a major modulator for striatal DA activity (De Deurwaerdère and Di Giovanni, 2017), but also 5-HT2 receptors play an important role in DA release in the NAc (De Deurwaerdère and Spampinato, 2001). Also in chicken, explicit roles for the somatodendritic 5-HT1A autoreceptor and postsynaptic 5-HT1B receptor in DA activity have been found (Dennis et al., 2013a).
Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications
2017, Progress in NeurobiologyCitation Excerpt :It is remarkable that the 5-HT2C receptor-dependent inhibitory effect is not observed when endogenous 5-HT tone is increased (De Deurwaerdere and Spampinato, 1999). Conversely, the systemic administration of numerous drugs sharing the ability to block 5-HT2C receptors such as SB-206553, SB-242084, SB-243413 have been shown to enhance DA release in the cortex, NAc and striatum (Berg et al., 2006; De Deurwaerdere et al., 2004; De Deurwaerdere and Spampinato, 2001; Gobert et al., 2000; Hovelso et al., 2011; Navailles et al., 2006a; Visser et al., 2015). Although this could suggest the existence of a tonic inhibitory control on DA function exerted by 5-HT on 5-HT2C receptors, one has to question why it does not similarly occur with all 5-HT2C antagonists.
5-HT2C receptors in psychiatric disorders: A review
2016, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :5-HT2CR stimulation may partly modulate the neurochemical and behavioral effects of psychostimulants by altering accumbal DA and/or glutamate levels (Pandey et al., 2006). The inhibitory activity of the dopaminergic pathways projecting to the FC, the mesolimbic and nigrostriatal pathways innervating the NAc and striatum can be modulated by receptors 5-HT2C (Alex and Pehek, 2007; De Deurwaerdere and Spampinato, 2001; Gobert et al., 2000; Millan et al., 2000b). It seems that activity of mesocortical/mesolimbic dopaminergic and noradrenergic projections (neurons) are under the control of a tonic and phasic inhibitory of 5-HT2CRs, (Di Matteo et al., 1999, 2000b; Millan et al., 1998).
New therapeutic opportunities for 5-HT<inf>2C</inf> receptor ligands in neuropsychiatric disorders
2016, Pharmacology and Therapeutics